Arvind Dasari, MD, MS

home / authors / arvind-dasari-md-ms

Articles

Experts Discuss Impact of Fruquintinib Approval in Metastatic CRC

November 10th 2023

Arvind N. Dasari, MD, lead investigator of the FRESCO-2 trial, spoke about the recent approval of fruquintinib for patients with previously treated metastatic colorectal cancer.

Arvind N. Dasari, MD, and Cathy Eng, MD, discuss clinical trial data that may support the FDA approval of fruquintinib in metastatic colorectal cancer, and how it may impact the standard of care.

Pipeline Perspectives: Fruquintinib in Metastatic Colorectal Cancer

Arvind Dasari, MD, MS;Cathy Eng, MD

October 2nd 2023

Arvind N. Dasari, MD, and Cathy Eng, MD, discuss clinical trial data that may support the FDA approval of fruquintinib in metastatic colorectal cancer, and how it may impact the standard of care.

Unmet Needs and Future Perspectives on Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

June 5th 2023

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in colorectal cancer.

Trials Focused on ctDNA in Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 29th 2023

An expert panel discusses clinical trials focused on circulating tumor DNA in guiding treatment selection in colorectal cancer.

Arvind Dasari, MD, MS, an expert on colorectal cancer

SUNLIGHT and FRESCO-2 Trials in Refractory Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 29th 2023

An overview of the SUNLIGHT and FRESCO-2 studies in the refractory colorectal cancer space.

Colorectal Cancer: Insights on ctDNA and Retesting for HER2 Expression

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 22nd 2023

A panel of experts discuss the role of ctDNA and their practices for retesting HER2 expression to guide treatment for colorectal cancer.

T-DXd in Patients With HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 22nd 2023

A comprehensive overview of trastuzumab deruxtecan (T-DXd) as a treatment for patients with HER2+ metastatic colorectal cancer.

Patient Profile: A 40-Year-Old Woman With Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 15th 2023

Experts on colorectal cancer present the case of a 40-year-old woman with CRC, who receives later-line treatment with trastuzumab deruxtecan, and share their initial thoughts.

Metastatic CRC: Role of ctDNA in Treatment Selection

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 15th 2023

Insights on the role of circulating tumor DNA in treatment selection for patients with metastatic colorectal cancer.

PARADIGM Trial: Recent Data on EGFR-Targeting Therapy for mCRC

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 8th 2023

Arvind Dasari, MD, MS, reviews the PARADIGM study on EGFR-targeting therapy in metastatic colorectal cancer.

Patient Profile: A 47-Year-Old Woman With HER2+ CRC and Early Disease Progression

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 8th 2023

Expert oncologists present the case of a 47-year-old woman with colorectal cancer and early disease progression, and discuss treatment options with the ongoing MOUNTAINEER-03 study.

MOUNTAINEER: Tucatinib Plus Trastuzumab in HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 1st 2023

Experts on HER2+ metastatic colorectal cancer review the MOUNTAINEER study on tucatinib plus trastuzumab.

Treatment Landscape for HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 1st 2023

An overview of the treatment landscape for HER2+ metastatic colorectal cancer and recent updates to the NCCN Guidelines.

Overview of HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

April 24th 2023

Expert oncologists discuss the landscape surrounding HER2+ metastatic CRC, including recommendations for biomarker testing and an overview of scoring criteria.

Patient Profile: A 46-Year-Old Woman With HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

April 24th 2023

A panel of expert oncologists present the case of a 46-year-old woman with HER2+ metastatic colorectal cancer, who is treated with tucatinib in the second-line setting.

Clinical Trials in Progress: CIRCULATE-US

Arvind Dasari, MD, MS;Christopher H. Lieu, MD

October 14th 2022

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US): a prospective phase 2/3 trial of MRD-based adjuvant therapy for patients with early-stage colon cancer with intensified and deintensified adjuvant therapy approaches using ctDNA status as a surrogate for MRD status (NRG-GI008) (NCT05174169).

Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US

Ibrahim Halil Sahin, MD;Yan Lin, PhD;Greg Yothers, PhD;Peter C. Lucas, MD, PhD;Dustin Deming, MD;Thomas J. George, MD;Scott Kopetz, MD, PhD;Christopher H. Lieu, MD;Arvind Dasari, MD, MS

October 14th 2022

Ibrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.

Gastrointestinal Neuroendocrine Tumors: Slow but Steady Progress

Arvind Dasari, MD, MS;James C. Yao, MD

September 15th 2014

In spite of recent encouraging developments in the setting of GI neuroendocrine tumors, many clinical questions remain to be answered and will be highlighted in this commentary.

Recurrent Pancreatic Adenocarcinoma After Pancreatic Resection

Arvind Dasari, MD, MS;Martin Mccarter, MD;Martine C. Mcmanus, MD;Paul Russ, MD;Wells A. Messersmith, MD, FACP

December 15th 2010

The University of Colorado Denver School of Medicine faculty hold weekly second opinion conferences focusing on cancer cases that represent most major cancer sites. Patients seen for second opinions are evaluated by an oncologic specialist. Their history, pathology, and radiographs are reviewed during the multidisciplinary conference, and then specific recommendations are made. These cases are usually challenging, and these conferences provide an outstanding educational opportunity for staff, fellows, and residents in training.The second opinion conferences include actual cases from genitourinary, lung, melanoma, breast, neurosurgery, gastrointestinal, and medical oncology. On an occasional basis, ONCOLOGY will publish the more interesting case discussions and the resultant recommendations. We would appreciate your feedback; please contact us at second.opinion@uchsc.edu.

<1 2